Trading Concept
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
No Result
View All Result
Trading Concept
No Result
View All Result
Home Trading News

Moderna shares fall after company cuts 2021 forecast for Covid vaccine sales

by
November 4, 2021
in Trading News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Moderna shares fell by more than 16% on Thursday after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.

The company said some doses for delivery this year have been shifted to early 2022 amid production issues and as it prioritizes deliveries to low-income countries through COVAX, the U.N.-backed effort to share coronavirus vaccines. It now expects Covid vaccine sales of between $15 billion and $18 billion this year, down from an earlier projection of $20 billion.

RELATED POSTS

Best Options Prop Trading Firms (2023) | 13 Top Prop Firms for Options Trading

May Employment Preview

In releasing its third-quarter earnings, Moderna said it is now expecting to deliver between 700 million and 800 million doses this year, down from its previous expectations of between 800 million and 1 billion doses. The company also said it projects sales of $17 billion to $22 billion in 2022.

By comparison, Pfizer has said it expects Covid vaccine sales of $36 billion this year and $29 billion in 2022.

Here’s how Moderna did compared with what Wall Street expected, according to average estimates compiled by Refinitiv:

EPS: $7.70 per share versus $9.05 per share expectedRevenue: $4.97 billion versus $6.21 billion expected

“We are humbled to have helped hundreds of millions of people around the world with our COVID-19 vaccine and yet we know our work is not done,” Moderna CEO Stephane Bancel said in a statement.

He said the company is working to ensure the vaccine is available in low-income countries by providing approximately 10% of its 2021 volume to them, and “significantly more” volume next year.

On a post-earnings call with investors, Bancel said the company’s supply chain became “more complex,” impacting international deliveries of its vaccine.

“We’ve increased deliveries to many countries around the world,” he said. “At the beginning of the year, we supplied to just a few large countries.”

Moderna Chief Financial Officer David Meline said the company continues to scale up its production network and is “working to achieve an increase quarter-over-quarter improvement starting in Q4.”

Moderna’s Covid vaccine is the company’s only commercialized product. The earnings report comes two weeks after the Food and Drug Administration authorized booster shots of Moderna’s vaccine to tens of millions of Americans.

The company said Thursday it anticipates commercial booster market sales could be up to $2 billion in 2022.

ShareTweetPin

Related Posts

Best Options Prop Trading Firms (2023) | 13 Top Prop Firms for Options Trading

by
June 2, 2023
0

As a seasoned options trader, you’ve decided it’s time to up your game by joining a proprietary trading firm. The...

May Employment Preview

by
June 2, 2023
0

by Calculated Risk on 6/01/2023 02:34:00 PM On Friday at 8:30 AM ET, the BLS will release the employment report...

U.S. Births decreased Slightly in 2022

by
June 2, 2023
0

by Calculated Risk on 6/01/2023 03:00:00 PM From the National Center for Health Statistics: Births: Provisional Data for 2022. The...

Friday: Employment Report

by
June 2, 2023
0

by Calculated Risk on 6/01/2023 09:01:00 PM Note: Mortgage rates are from MortgageNewsDaily.com and are for top tier scenarios. Friday:...

Here’s what to watch out for in Friday’s jobs report for May

by
June 2, 2023
0

Construction workers on a job site on May 05, 2023 in Miami, Florida. Joe Raedle | Getty Images Watching the...

Next Post

Hotels: Occupancy Rate Down 6% Compared to Same Week in 2019

Bezos' Blue Origin loses lawsuit against NASA over SpaceX lunar lander contract

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:



By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

MOST VIEWED

  • WHO says Covid vaccine booster programs will prolong pandemic

    0 shares
    Share 0 Tweet 0
  • Forget Tesla — this auto stock is the one to buy right now, analyst says

    0 shares
    Share 0 Tweet 0
  • Spin or Split? AT&T Has a Big Decision to Make on Discovery Stake.

    0 shares
    Share 0 Tweet 0
  • Here’s how Carl Icahn is positioning for a possible recession in America

    0 shares
    Share 0 Tweet 0
  • Some lawmakers and their families are betting thousands of dollars on crypto

    0 shares
    Share 0 Tweet 0
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
All rights reserved by tradingconcept.net
No Result
View All Result
  • Email Whitelisting
  • Home
  • Privacy Policy

All rights reserved by www.tradingconcept.net